KR101436753B1 - Anti obesity composition comprising licorice extracts and preparation method thereof - Google Patents
Anti obesity composition comprising licorice extracts and preparation method thereof Download PDFInfo
- Publication number
- KR101436753B1 KR101436753B1 KR1020130106321A KR20130106321A KR101436753B1 KR 101436753 B1 KR101436753 B1 KR 101436753B1 KR 1020130106321 A KR1020130106321 A KR 1020130106321A KR 20130106321 A KR20130106321 A KR 20130106321A KR 101436753 B1 KR101436753 B1 KR 101436753B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- licorice
- group
- composition
- present
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- 239000000284 extract Substances 0.000 title claims description 67
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 title claims description 19
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 title claims description 17
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 title claims description 17
- 229940010454 licorice Drugs 0.000 title claims description 17
- 240000004670 Glycyrrhiza echinata Species 0.000 title claims 2
- 230000003579 anti-obesity Effects 0.000 title description 2
- 238000002360 preparation method Methods 0.000 title description 2
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 229940069445 licorice extract Drugs 0.000 abstract description 33
- 230000000694 effects Effects 0.000 abstract description 27
- 230000037147 athletic performance Effects 0.000 abstract description 20
- 230000002708 enhancing effect Effects 0.000 abstract description 8
- 239000004615 ingredient Substances 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 244000303040 Glycyrrhiza glabra Species 0.000 description 17
- 238000000605 extraction Methods 0.000 description 14
- 238000000034 method Methods 0.000 description 13
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 12
- 210000003205 muscle Anatomy 0.000 description 12
- 229920002527 Glycogen Polymers 0.000 description 11
- 230000003247 decreasing effect Effects 0.000 description 11
- 229940096919 glycogen Drugs 0.000 description 11
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 11
- 229960004949 glycyrrhizic acid Drugs 0.000 description 11
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 11
- 235000019410 glycyrrhizin Nutrition 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 239000000469 ethanolic extract Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 239000004378 Glycyrrhizin Substances 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 235000009200 high fat diet Nutrition 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 238000000194 supercritical-fluid extraction Methods 0.000 description 7
- 235000013361 beverage Nutrition 0.000 description 6
- 238000002481 ethanol extraction Methods 0.000 description 6
- 239000004310 lactic acid Substances 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 210000001789 adipocyte Anatomy 0.000 description 5
- 210000003486 adipose tissue brown Anatomy 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 235000018823 dietary intake Nutrition 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- LBQIJVLKGVZRIW-ZDUSSCGKSA-N glabridin Chemical compound C1([C@H]2CC3=CC=C4OC(C=CC4=C3OC2)(C)C)=CC=C(O)C=C1O LBQIJVLKGVZRIW-ZDUSSCGKSA-N 0.000 description 4
- 229940093767 glabridin Drugs 0.000 description 4
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 description 4
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 description 4
- 238000003809 water extraction Methods 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000029549 Muscle injury Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 201000010063 epididymitis Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000001685 glycyrrhizic acid Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- DRCWOKJLSQUJPZ-DZGCQCFKSA-N (4ar,9as)-n-ethyl-1,4,9,9a-tetrahydrofluoren-4a-amine Chemical compound C1C2=CC=CC=C2[C@]2(NCC)[C@H]1CC=CC2 DRCWOKJLSQUJPZ-DZGCQCFKSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 101001008429 Homo sapiens Nucleobindin-2 Proteins 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- 102100027441 Nucleobindin-2 Human genes 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 102000013394 Troponin I Human genes 0.000 description 2
- 108010065729 Troponin I Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 210000000593 adipose tissue white Anatomy 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 235000003228 Lactuca sativa Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 238000007707 calorimetry Methods 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000037080 exercise endurance Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- -1 infusions Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 감초 추출물을 유효성분으로 함유하는 지구력 내지 운동능력 증진용 조성물을 제공하며, 특히 이러한 기능과 관련되는 것으로 판단되는 유효성분들의 함량을 극대화하여 지구력 내지 운동능력에 보다 탁월한 효과를 제공하는 조성물 및 그 제조방법을 제공한다.The present invention provides a composition for enhancing endurance or athletic performance comprising the licorice extract as an active ingredient, and more particularly, to a composition for maximizing the content of effective ingredients judged to be related to such a function to provide more excellent effects on endurance or athletic performance And a method for producing the same.
Description
본 발명은 감초 추출물을 유효성분으로 함유하는 조성물에 관한 것으로, 보다 상세하게는 감초 추출물을 함유하는 지구력 내지 운동능력 증진용 조성물 및 제조방법으로, 특히 이러한 기능과 관련되는 것으로 판단되는 유효성분들의 함량을 극대화하여 지구력 내지 운동능력에 보다 탁월한 효과를 제공하는 조성물 및 그 제조방법에 관한 것이다.The present invention relates to a composition containing an extract of licorice root as an active ingredient and more particularly to a composition for endurance or athletic performance enhancement containing a licorice extract and a method of producing the same, To provide a more excellent effect on endurance or athletic performance, and a method of manufacturing the same.
육체적 운동능력을 향상시키기 위한 보조제, 기능성 식품, 식품 조성물 등의 연구는 오랫동안 지속되어 왔으며 실제로 스테로이드, 카페인 등등의 화합물을 복용하면 운동능력을 증가시킬 수도 있다. 그러나 이러한 약물은 치명적인 부작용을 동반할 수 있으므로 극히 그 사용이 제한되고 있는 것이 사실이다.Research into the use of adjuvants, functional foods, food compositions, etc. to improve physical athletic performance has been ongoing for a long time and actually taking a compound such as steroids, caffeine, etc. may increase exercise capacity. These drugs, however, can be accompanied by fatal side effects, so their use is extremely limited.
감초는 예로부터 식품의 조미료나 약용으로서 사용되어 왔으며, 특히 주성분인 글리시리진(Glycyrrhizin)은 자당의 150배의 감도가 있으며, 감미료로서 현재에도 널리 사용되고 있다. 한편으로, 감초 추출물에는 항궤양 작용(Takagi, K., Ishii, Y. : Arzein Forsch, 17, 1544 (1967)) 이나 간 장해 보호 작용 등의 약리 작용이 있다는 것이 알려져 있다.Glycyrrhizin has been used as a food seasoning or medicament for a long time. In particular, Glycyrrhizin, which is a main ingredient, has a sensitivity of 150 times that of sucrose and is widely used as a sweetener. On the other hand, it is known that licorice extract has a pharmacological action such as anti-ulcer action (Takagi, K., Ishii, Y.: Arzein Forsch, 17, 1544 (1967)) or hepatic injury protection.
감초의 이와 같은 다양한 효과에 관한 연구들이 있어 왔지만, 육체적 운동능력에 대한 증진 효과에 관하여는 알려진 바가 없다. 본 발명에서는 종래 한방재료로서 치명적인 부작용이 없으면서 지구력 내지 운동능력 증진의 개선효과가 뚜렷한 천연소재를 찾던 중 감초의 추출물이 이러한 요구를 만족할 수 있음을 발견하여 본 발명에 이르게 되었다. There have been studies on these various effects of licorice, but there is no known effect of enhancing physical exercise ability. In the present invention, it has been found that the extract of licorice can satisfy this demand while seeking a natural material which has no fatal side effect as a herbal ingredient and has a marked effect of improving endurance or athletic performance improvement.
본 발명은 상기한 바와 같이 종래 기술이 가지는 이러한 과제를 해결하기 위해 안출된 것으로, 그 목적은 감초 추출물을 함유하는 지구력 내지 운동능력 증진용 조성물 및 제조방법을 제공함에 있다.Disclosure of Invention Technical Problem [8] Accordingly, the present invention has been made to solve the above-mentioned problems of the prior art, and its object is to provide a composition for enhancing endurance or athletic performance containing the licorice extract and a manufacturing method thereof.
본 발명의 다른 목적으로는 특히 지구력 내지 운동능력 증진과 관련되는 것으로 판단되는 유효성분들의 함량을 극대화하여 지구력 내지 운동능력에 보다 탁월한 효과를 제공하는 조성물 및 그 제조방법을 제공함에 있다. Another object of the present invention is to provide a composition for maximizing the content of active ingredients, which is considered to be related to endurance or athletic performance improvement, to provide more excellent effects on endurance or athletic performance, and a method for producing the same.
상기한 바와 같은 본 발명의 기술적 과제는 다음과 같은 수단에 의해 달성되어진다.The technical problem of the present invention as described above is achieved by the following means.
(1) 감초 추출물을 유효성분으로 함유하는 지구력 내지 운동능력 증진용 조성물.(1) A composition for enhancing endurance or athletic performance containing an licorice extract as an active ingredient.
(2) 제 1항에 있어서,(2) The method according to
감초 추출물은 열수 추출물인 것을 특징으로 하는 지구력 내지 운동능력 증진용 조성물.Wherein the licorice extract is a hot-water extract.
(3) 제 1항에 있어서,(3) The method according to
감초 추출물은 에탄올 추출물 또는 에탄올을 추출용매로 하는 초임계 추출물인 것을 특징으로 하는 지구력 내지 운동능력 증진용 조성물.Wherein the licorice extract is a supercritical extract comprising an ethanol extract or ethanol as an extraction solvent.
(4) 제 1항에 있어서,(4) The method according to
감초 추출물은 열수 추출물과, 상기 열수추출과정에서 얻어진 침전물을 대상으로 하는 에탄올 추출물의 혼합물인 것을 특징으로 하는 지구력 내지 운동능력 증진용 조성물.Wherein the licorice extract is a mixture of a hot water extract and an ethanol extract which is a precipitate obtained in the hot water extraction process.
(5) 제 1항에 있어서,(5) The method according to
감초 추출물은 에탄올 추출물과, 상기 에탄올 추출과정에서 얻어진 침전물의 열수추출물로 이루어지는 혼합물인 것을 특징으로 하는 지구력 내지 운동능력 증진용 조성물.Wherein the licorice extract is a mixture of an ethanol extract and a hot water extract of the precipitate obtained in the ethanol extraction step.
(6) 제 1항에 있어서,(6) The method according to
얼레지 추출물을 더 포함하는 것을 특징으로 하는 지구력 내지 운동능력 증진용 조성물.The composition for enhancing endurance or athletic performance as claimed in
(7) 감초를 열수로 추출하여 글리시리진을 활성성분으로 주로 함유하는 제1추출물을 얻는 단계;(7) extracting licorice with hot water to obtain a first extract mainly containing glycyrrhizin as an active ingredient;
상기 열수 추출과정에서 얻어진 침전물을 에탄올추출 또는 초임계 추출하여 글라브리딘을 활성성분으로 주로 함유하는 제2추출물을 얻는 단계; 및Extracting the precipitate obtained in the hot water extraction step with ethanol or supercritical extraction to obtain a second extract containing glyburidine as an active ingredient; And
상기 제1추출물과 제2추출물을 혼합하는 단계;Mixing the first extract and the second extract;
를 포함하는 지구력 내지 운동능력 증진용 감초추출물의 제조방법.Wherein the method comprises the steps of:
(8) 감초를 에탄올 추출 또는 초임계 추출하여 글라브리딘을 활성성분으로 주로 함유하는 제1추출물을 얻는 단계;(8) extracting licorice with ethanol or supercritical extraction to obtain a first extract mainly containing glabridin as an active ingredient;
상기 에탄올 추출과정에서 얻어진 침전물을 열수로 추출하여 글리시리진을 활성성분으로 주로 함유하는 제2추출물을 얻는 단계; 및Extracting the precipitate obtained in the ethanol extraction step with hot water to obtain a second extract mainly containing glycyrrhizin as an active ingredient; And
상기 제1추출물과 제2추출물을 혼합하는 단계;Mixing the first extract and the second extract;
를 포함하는 지구력 내지 운동능력 증진용 감초추출물의 제조방법.Wherein the method comprises the steps of:
상기 실시 예에서 상세히 기술한 바와 같이, 본 발명에 따른 감초 추출물을 함유하는 조성물은 기존에 알려진 일반적인 기능 외에 지구력 내지 운동능력을 개선하는 효과를 제공한다. 특히 이러한 기능과 관련되는 것으로 판단되는 유효성분들의 함량을 극대화하여 지구력 내지 운동능력에 보다 탁월한 효과를 제공하는 조성물을 제공할 수 있다.As described in detail above, the composition containing the licorice extract according to the present invention provides an effect of improving endurance or athletic performance in addition to the conventional functions known in the art. In particular, it is possible to provide a composition that maximizes the content of effective ingredients that are considered to be related to such a function, thereby providing more excellent effects on endurance or athletic performance.
도 1은 감초를 대상으로 하는 추출용매별 HPLC 분석 크로마토그램.
도 2는 감초를 대상으로 하는 추출조건에 따른 기능성분 함유량 변화.
도 3은 감초 추출물 종류별 고지방 식이 급여 운동 마우스의 체중증가에 미치는 영향을 측정한 결과.
도 4는 본 발명에 따른 추출물을 이용하여 실험한 실험군별 체중 증가량을 측정한 결과.
도 5는 본 발명에 따른 추출물을 이용하여 실험한 마우스의 일별 평균 식이 섭취량을 측정한 결과.
도 6은 본 발명에 따른 추출물을 이용하여 실험한 실험 식이 급여 6, 9주 후 운동 지구력 시험 결과.
도 7은 본 발명에 따른 감초 추출물 급여의 종류에 따른 마우스의 장기무게 비교.
도 8은 본 발명에 따른 추출물을 이용하여 실험한 간, 백색지방 및 갈색지방의 조직학적 분석결과.
도 9는 본 발명에 따른 추출물을 이용하여 실험한 혈중 지질 변화를 측정한 결과.
도 10은 본 발명에 따른 추출물을 이용하여 실험한 간조직 내 총 지방량, TC 및 TG 변화.
도 11은 본 발명에 따른 추출물을 이용하여 실험한 간의 CPK 와 글리코겐 함량 변화.
도 12는 본 발명에 따른 추출물을 이용하여 실험한 근육의 젖산과 글리코겐 함량 변화
도 13은 본 발명에 따른 추출물을 이용하여 실험한 근육의 젖산과 glycogen 함량 변화
도 14는 본 발명에 따른 추출물을 이용하여 지근 (slow and aerobic type I muscle) 마커인 트로포닌 I(troponin I)과 속근 마커인 MyHCIIb의 유전자 발현을 측정한 결과 .
도 15는 본 발명에 따른 감초추출물과 얼레지추출물의 혼합적용에 의한 지방세포 사멸효과를 측정한 결과.FIG. 1 is a chromatogram of HPLC analysis of extracted solvents for licorice.
FIG. 2 shows changes in the content of functional ingredients according to extraction conditions for licorice.
FIG. 3 shows the results of measuring the effect of the high-fat dietary extract of licorice extract on the weight gain of exercise mice.
FIG. 4 shows the results of measuring the weight gain of each experimental group using the extract of the present invention.
FIG. 5 is a graph showing the average daily dietary intake of the mice tested with the extract of the present invention.
FIG. 6 shows the results of exercise endurance test after 6 and 9 weeks of the experimental diet experiment using the extract of the present invention.
FIG. 7 is a graph comparing long term weights of mice according to the kind of licorice extracts according to the present invention.
FIG. 8 shows the results of histological analysis of liver, white fat and brown fat using the extract of the present invention.
FIG. 9 shows the result of measurement of blood lipid changes by using the extract of the present invention.
FIG. 10 shows changes in total fat mass, TC and TG in liver tissues experimented with the extract of the present invention.
Figure 11 shows changes in CPK and glycogen content in the liver after the experiment using the extract of the present invention.
Figure 12 shows the changes in lactic acid and glycogen content of muscle tested with the extract of the present invention
Figure 13 shows the changes in lactic acid and glycogen content of muscle tested with the extract of the present invention
FIG. 14 shows gene expression of troponin I and myHCIIb, a slow and aerobic type I muscle marker, using the extract according to the present invention.
FIG. 15 is a result of measurement of fat cell killing effect by the mixed application of licorice extract and lettuce extract according to the present invention.
이하 본 발명의 내용을 보다 상세하게 설명하면 다음과 같다.Hereinafter, the contents of the present invention will be described in more detail.
본 발명은 감초 추출물을 유효성분으로 함유하는 지구력 내지 운동능력 증진용 조성물을 포함한다.The present invention includes a composition for enhancing endurance or athletic performance containing an licorice extract as an active ingredient.
상기 본 발명 조성물에서의 감초 추출물은 열수 추출물, 에탄올 추출물(물과의 혼합물을 포함, 이하 별도의 언급이 없는 한 에탄올 추출물로 통칭함), 초임계 추출물 또는 이들 추출물의 혼합물을 포함한다.The licorice extract in the composition of the present invention includes hot water extract, ethanol extract (including a mixture with water, hereinafter collectively referred to as an ethanol extract unless otherwise noted), supercritical extract or a mixture of these extracts.
열수 추출물의 경우 1∼10배의 물을 가하여 1 내지 2기압, 80∼120℃하에 1∼12시간 추출하는 것이 바람직하다. 에탄올 추출물의 경우 50 내지 100% 에탄올로 이루어진 추출용매를 이용할 수 있고, 초임계 추출물은 에탄올을 추출용매로 하여 250 내지 350bar의 압력하에 수행되어질 수 있다.In the case of the hot-water extract, it is preferable to add 1 to 10 times of water and extract at 1 to 2 atm and 80 to 120 캜 for 1 to 12 hours. The ethanol extract may be an extraction solvent composed of 50 to 100% ethanol, and the supercritical extract may be performed under the pressure of 250 to 350 bar using ethanol as an extraction solvent.
본 발명 조성물에서의 감초 추출물은 글리시리진 또는/및 글라브리딘을 주 활성성분으로 함유하며, 이들은 아직 밝혀지지 않은 기작에 의해 직ㆍ간접적으로 각각 지구력 강화 내지 운동능력 증진에 기여하는 것으로 판단된다. 본 발명에서는 이들 성분들을 함유하는 감초 추출물이 열수 추출물의 형태일 경우 주로 글리시리진이 다량으로 함유되며, 에탄올 추출물과 초임계 추출물에서는 글라브리딘이 주성분으로 함유되는 것을 확인하였으며, 각 추출물 모두에서 지구력 강화 내지 운동능력 증진에 탁월한 효과를 발휘하는 것을 확인하였다.The licorice extract in the composition of the present invention contains glycyrrhizin and / or gabridin as the main active ingredient, and these factors are directly or indirectly attributed to enhancement of endurance or athletic ability by the mechanism not yet revealed. In the present invention, it was confirmed that the licorice extract containing these components contained mainly glycyrrhizin in the case of the hot-water extract, and the glabridin was contained as the main component in the ethanol extract and the supercritical extract. Or exercise capacity of the human body.
이러한 의미에서 본 발명에서의 감초 추출물은 바람직하게는 열수 추출물과, 에탄올 추출물 또는 초임계 추출물의 혼합 추출물이 보다 적합하다. 수율의 극대화를 위하여 감초를 열수로 추출하여 1차 추출물을 얻은 후, 상기 1차 추출과정에서 얻은 침전물을 에탄올 등 또는 초임계 추출방법에 의해 재차 추출하는 것에 의해 글리시리진과 글라브리딘이 다량 함유된 추출물을 얻을 수 있다. 마찬가지로 감초를 에탄올 등 또는 초임계 추출방법으로 추출하여 1차 추출물을 얻은 후, 상기 1차 추출과정에서 얻은 침전물을 열수추출 방법에 의해 재차 추출하는 것도 위 경우에서와 같이 활성성분의 수율을 극대화하는 것이 가능하다.In this sense, the licorice extract in the present invention is preferably a hydrothermal extract, a mixed extract of an ethanol extract or a supercritical extract. In order to maximize the yield, the licorice is extracted with hot water to obtain a first extract, and the precipitate obtained in the first extraction step is extracted again with ethanol or the like by supercritical extraction method to obtain a solution containing a large amount of glycyrrhizin and glabridin An extract can be obtained. Likewise, extracting the licorice with ethanol or the supercritical extraction method to obtain the first extract, and then extracting the precipitate obtained in the first extraction step again by the hot water extraction method can maximize the yield of the active ingredient It is possible.
본 발명에서는 각 경우에서의 2차 추출과정에서 얻어진 침전물에 헥산, 클로로포름, 또는 에틸아세테이트로 재차 추출한 추출물을 더 포함하는 것이 바람직하다. 이들 추출물은 전체 조성물의 중량대비 0.1 내지 10 중량%의 범위에서 첨가되어질 수 있으며, 이들 추출물을 추가로 첨가한 실험군에서 동일함량 대비 타 조성물군에 비하여 지구력 내지 운동능력의 개선효과가 보다 우수한 것으로 나타났다.In the present invention, it is preferable that the precipitate obtained in the second extraction step in each case further contains an extract once again extracted with hexane, chloroform, or ethyl acetate. These extracts can be added in a range of 0.1 to 10% by weight relative to the weight of the whole composition. In the experimental group to which these extracts were further added, the effect of improving endurance or athletic performance was better than that of other composition groups .
본 발명의 조성물은 상기한 지구력 내지 운동능력의 개선효과 외에 비만억제활성을 더욱 보강하기 위해 얼레지 추출물을 더 포함할 수 있다. 얼레지 추출물은 열수추출물 또는 에탄올 등 추출물일 수 있으며, 본 발명자의 실험에 의하면 운동능력을 저해함이 없이 비만억제활성이 우수한 것으로 확인되었다. 이러한 얼레지 추출물은 전체 조성물의 함량 대비 1 내지 10 중량%의 범위에서 첨가되는 것이 좋다.
The composition of the present invention may further include an extract of Aldergia to further enhance the activity of inhibiting obesity, in addition to the above-described effect of improving endurance or athletic performance. The extract can be an extract such as hot water extract or ethanol, and according to the experiment of the present inventor, it was confirmed that the activity of inhibiting obesity is excellent without inhibiting the exercise capacity. It is preferable that such an extract is added in an amount of 1 to 10% by weight relative to the content of the whole composition.
본 발명에 따른 조성물은 약제, 식품 및 음료 등에 다양하게 이용될 수 있다. 본 발명의 추출물을 첨가할 수 있는 식품으로는, 각종 식품류, 예를 들어, 음료, 껌, 차, 비타민 복합제, 건강보조 식품류 등이 있으며, 환제, 분말, 과립, 침제, 정제, 캡슐 또는 음료인 형태로 사용할 수 있다. 이때, 식품 또는 음료 중의 상기 추출물의 양은 일반적으로 본 발명의 건강식품 조성물의 경우 전체 식품 중량의 0.05 내지 30 중량%로 가할 수 있으며, 건강음료 조성물의 경우 100 ㎖를 기준으로 0.05 내지 30 g 가할 수 있다.The composition according to the present invention can be used variously in medicines, foods and beverages. Examples of the foods to which the extract of the present invention can be added include various foods such as beverages, gums, tea, vitamin complexes and health supplements. Examples of such foods include pills, powders, granules, infusions, tablets, Can be used. At this time, the amount of the extract in the food or beverage may generally be from 0.05 to 30% by weight of the total food weight of the health food composition of the present invention, and 0.05 to 30 g based on 100 ml of the health beverage composition have.
본 명세서에서 사용될 수 있는 식품보조첨가제는 당업계에 통상적인 식품첨가제, 예를 들어 향미제, 풍미제, 착색제, 충진제, 안정화제 등을 포함한다. 본 발명에 따른 건강 음료 조성물은 지시된 비율로 필수 성분으로서, 상기추출물을 외에 첨가되는 성분에 특별한 제한은 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상기 천연 탄수화물의 예로는 단당류, 예를 들어, 포도당, 과당 등; 이당류, 예를 들어 말토스, 슈크로스 등; 다당류, 예를 들어 덱스트린, 시클로덱스트린 등; 과 같은 통상적인 당 및 자일리톨, 솔비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등)) 및 합성 향미제(사카린, 아스파르탐 등)를 사용하는 것도 좋다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖당 일반적으로 약 0.5 내지 30 g이다.Food additive additives that can be used herein include food additives customary in the art, such as flavoring agents, flavoring agents, coloring agents, fillers, stabilizers, and the like. The health beverage composition according to the present invention is not particularly limited as to the ingredient to be added in addition to the above extract as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. Examples of the natural carbohydrate include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose, etc .; Polysaccharides such as dextrin, cyclodextrin and the like; And sugar alcohols such as xylitol, sorbitol, and erythritol. It is also possible to use natural flavoring agents (tau martin, stevia extract (for example, rebaudioside A, glycyrrhizin and the like) and synthetic flavoring agents (saccharin, aspartame, etc.) as flavors other than the above . The ratio of the natural carbohydrate is generally about 0.5 to 30 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 지구력 내지 운동능력 증진용 조성물은 다양한 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 충진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다.In addition to the above, the composition for enhancing endurance or athletic performance of the present invention may contain flavorings such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, colorants and fillers (cheese, chocolate etc.), pectic acid and its salts , Alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks and the like.
그밖에 본 발명의 조성물은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 특별히 한정되지는 않지만 본 발명의 조성물 100 중량부에 대하여 0 내지 약 10 중량부의 범위에서 선택되는 것이 일반적이다.In addition, the composition of the present invention may contain natural fruit juice and pulp for the production of fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The ratio of such additives is not particularly limited, but is generally selected in the range of 0 to about 10 parts by weight based on 100 parts by weight of the composition of the present invention.
본 발명의 상기 감초 추출물을 유효성분으로 함유하는 지구력 내지 운동능력 증진용 조성물은 목적하는 바에 따라 비경구 투여하거나 경구 투여할 수 있으며, 하루에 체중 1㎏ 당 0.001 내지 5g의 양을 1 내지 수회에 나누어 투여할 수 있다. 특정 환자에 대한 투여용량 수준은 환자의 체중, 연령, 성별, 건강상태, 식이, 투여시간, 투여 방법, 흡수율, 질환의 중증도 등에 따라 변화될 수 있다.The composition for enhancing endurance or athletic performance containing the licorice extract of the present invention as an active ingredient may be administered parenterally or orally in accordance with the purpose and may be administered in an amount of 0.001 to 5 g per 1 kg of body weight per day Can be administered separately. The dosage level for a particular patient may vary depending on the patient's body weight, age, sex, health condition, diet, time of administration, method of administration, rate of absorption, severity of the disease,
이하 본 발명의 내용을 실시예에 의해 보다 상세하게 설명하기로 한다. 다만 이들 실시예는 본 발명의 내용을 이해하기 위해 제시되는 것일 뿐 본 발명의 권리범위가 이들 실시예에 한정되어지는 것으로 해석되어져서는 아니된다.
Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood, however, that these examples are provided so that the scope of the present invention is not limited thereto.
<실시예 1> 추출용매별 조추출물의 제조Example 1 Preparation of crude extracts by extraction solvent
추출용매의 극성에 따라 용출되는 목적 기능 성분의 변화를 측정하고자 감초의 열수 추출, 95% 에탄올 추출 및 초임계 추출을 실시하였다. 추출용매에 따른 추출조건 및 수율은 표 1과 같다.Extraction of 95% ethanol and supercritical extraction of licorice were carried out to measure the change of the objective functional component eluted according to the polarity of the extraction solvent. Table 1 shows the extraction conditions and yields according to the extraction solvent.
극성차이가 대비되는 두 가지 용매 (열수, 에탄올)와 초임계추출물에 있어서의 기능성분 용출의 변화를 확립된 동시 분석 조건을 활용하여 HPLC 분석을 통해 확인하고 (도 1), 이를 정량화 하여 기능성분 함유량의 차이를 측정하였다 (도 2).The changes in dissolution of functional components in supercritical extracts with two solvents (hot water, ethanol), which are contrasted with polarity differences, were confirmed by HPLC analysis using the established simultaneous analysis conditions (Fig. 1) (Fig. 2).
즉 극성용매를 사용한 열수 추출물의 경우, 글리시리진산(glycyrrhizic acid)의 함량이 뚜렷이 높았으며 비극성 용매를 사용한 95% 에탄올 추출물의 경우는 글리시리진산의 용출은 매우 낮았고 글라브리딘이 소량 용출되었다. 이와 달리, 초임계 추출의 경우, 글리시리진산의 함량은 낮고 글라브리딘이 다량 용출됨을 확인하였다.
Glycyrrhizic acid content was significantly higher in the case of hot water extracts using polar solvents. In the case of the 95% ethanol extract using a nonpolar solvent, the elution of glycyrrhizic acid was very low and a little amount of glabridin was eluted. On the contrary, in case of supercritical extraction, it was confirmed that the content of glycyrrhizic acid was low and that large amount of gabridine eluted.
<실험예 2> 비만 동물에서의 지구력 증강 효능 평가≪ Experimental Example 2 > Evaluation of endurance enhancement efficacy in obese animals
감초 유래의 항비만 효능 및 운동 수행능 증가의 효능을 동시에 지니는 소재를 개발하기 위해 추출용매별 감초 추출물 급여가 비만 동물의 체중 및 운동 수행능에 미치는 영향을 측정하였다. 4주령의 마우스를 구입하여 1주간의 적응 후 정상식이 급여군과 고지방 식이 급여군으로 나누어 4주 동안 실험 식이를 급여하였다. 4주간의 고지방 식이 급여 결과, 고지방 식이 급여로 인한 체중 증가가 나타나지 않는 마우스 (resistant to high fat diet-induced body weight increase)를 실험군에서 탈락시켜 실험동물 자체 특성의 차이를 배제하고자 하였다.The effect of licorice extract extracts on the weight and exercise performance of obese animals was investigated in order to develop a material having both anti - obesity effect and exercise performance increasing ability derived from licorice. Four weeks old mice were purchased, and after 1 week of adaptation, the experimental diet was fed for 4 weeks, divided into the saline group and the high fat diet group. As a result of the 4-week high-fat dietary diet, we tried to eliminate the differences in the characteristics of the experimental animals by eliminating the mice with high fat diet-induced body weight increase.
선별 후 각 그룹별로 10마리씩 배치하여 6그룹으로 나누어 9주 동안 실험식이를 급여하였다. 6군의 구성은 정상식이 급여군 (N), 고지방 식이를 급여한 운동군 (C-E), 감초 에탄올 추출물 1% 포함 고지방 식이를 급여한 운동군 (E-E), 감초 열수 추출물 1% 포함 고지방 식이를 급여한 운동군 (W-E), 감초 초임계 추출물 0.1% 또는 0.25 % 포함 고지방 식이를 급여한 운동군 (각각 SL-E, SH-E)으로 하였다.After selection, 10 rats were divided into 6 groups and fed the experimental diet for 9 weeks.
실험 시작 후 3, 6, 9 주에 트레드밀(treadmill) 운동을 시켰다. 15ㅀ 경사로 훈련은 첫날 5m/min의 속도로 15분간, 10m/min 5분간, 이틀째 5m/min의 속도로 10분간, 10m/min 10분간 시켰으며 시험날인 셋째날에는 10 m/min 으로 20분간 운동 후 2분마다 1 m/min으로 속도를 증가시켰다. 최대 운동 수행능은 운동을 멈춘 후 그리드(grid)에서 10초 이상 머무를 때까지의 달린 거리로 환산하였다.
Treadmill exercise was performed at 3, 6, and 9 weeks after the start of the experiment. 15 ㅀ The ramp training was carried out for 10 minutes at 10 m / min for 10 minutes at a rate of 5 m / min on the second day for 15 minutes, 10 m / min for 5 minutes and 15 minutes for the first day at a speed of 5 m / min. After the exercise, the speed was increased to 1 m / min every 2 minutes. The maximal exercise performance was converted to the running distance from the grid to the stay for more than 10 seconds after stopping the exercise.
(가) 체중 변화 및 식이 섭취량(A) Weight change and dietary intake
9주간의 실험기간 동안의 체중변화를 주별로 측정한 결과 W-E, SL-E 및 SH-E 그룹에서 유의적인 체중의 감소 경향이 나타났다 (도 3).The body weight changes during the 9-week experimental period were measured weekly, showing a significant decrease in weight in the W-E, SL-E and SH-E groups (FIG. 3).
9주간의 실험 기간 동안 체중 증가량을 비교한 결과 N-E군은 7.8g 증가 (비운동 군에 비해 0.85g 감소)한 반면 C-E 그룹은 14.02g 증가 (비운동군 실험군에 비해 0.1g 감소)하였다. W-E 및 SH-E 그룹은 체중 증가가 각각 8.96g, 6.86g 으로 유의적으로 감소하였으며 이는 비운동군의 8.76g, 9.14와 비교시 SH-E 그룹의 경우 운동에 의한 체중 감소 효능이 가장 높게 나타났다 (도 4). 그러나 실험기간 중의 식이 섭취량은 실험군별 차이는 나타나지 않아 (도 5) 식이 섭취량 감소에 따른 체중증가가 아닌 것으로 사료되었다.
Comparing the body weight gain during the 9-week experimental period, the NE group increased by 7.8 g (0.85 g compared to the non-exercise group) while the CE group increased by 14.02 g (0.1 g compared to the non-exercise group). WE and SH-E groups significantly decreased weight gain to 8.96g and 6.86g, respectively. The SH-E group showed the highest weight loss effect by exercise compared to 8.76g and 9.14 of non-exercise group 4). However, the dietary intake during the experimental period did not show any difference between the experimental groups (Fig. 5), suggesting that the dietary intake was not the weight gain due to the decreased intake.
(나) 최대 운동 수행능 (B) Maximum exercise performance
감초 추출물의 급여가 비만 동물의 운동 수행능에 미치는 영향을 측정하고자, 실험식이 급여 3, 6, 9주 후에 트레드밀 운동을 통해 최대 운동 수행능을 마우스가 지칠 때까지 이동한 거리 (distance to exhaustion)로 측정하였다. 그 결과 실험 식이 급여 6주 후 E-E, W-E 및 SH-E에서, 9주의 경우는 W-E 및 SH-E 그룹에서 운동 수행능의 증가가 나타났으며 특히, 9주의 SH-E 그룹의 경우 C-E에 비해 2.3 배 이상, N-E 그룹에 비해 1.3배 이상 최대 이동거리가 증가하여 지구력 증진에 매우 효과적으로 사료되었다 (도 6).
In order to measure the effect of the licorice extract on the exercise performance of obese animals, the empirical formula was calculated as distance to exhaustion after 3, 6, and 9 weeks of treadmill exercise, Respectively. As a result, the exercise performance was increased in EE, WE and SH-E after 6 weeks of feeding and in WE and SH-E groups in 9 weeks. Especially, in SH-E group of 9 weeks, 2.3 times higher than that of NE group and 1.3 times higher than that of NE group (Figure 6).
(다) 장기 무게(C) Organ weight
9주간의 실험식이 급여 후 각 그룹별 마우스의 장기무게 (간, 부고환 지방, 신장주위 지방 및 갈색지방)의 비교 결과 (도 7), 간의 경우 고지방 식이 급여로 인한 무게의 증가가 모든 감초 추출물 급여 그룹에서 유의적으로 감소하였다. 백색지방인 부고환 지방 및 신장주위지방의 경우 W-E 및 SH-E 그룹에서 C-E에 비해 유의적으로 감소하였다. 갈색지방의 경우는 모든 감초 추출물 급여 그룹에서 모두 통계적으로 유의한 감소를 보였다.
The results of the 9-week empirical formula showed that the weight of the liver due to high fat dietary supplementation was higher than that of all the licorice extract (Fig. 7) Group significantly decreased. In the case of epididymal fat and peripheral fat of white fat, WE and SH-E groups were significantly lower than CE. In the case of brown fat, all of the licorice extract group showed a statistically significant decrease.
(라) 조직학적 분석(D) Histological analysis
간 (Liver), 부고환 지방 (WAT) 및 갈색지방 (BAT)의 조직 관찰을 위해 포르말린 고정 조직 절편의 H&E stain 결과, 간의 경우, 장기 무게 측정시 나타났던 경향과 같이, 감초 추출물이 포함된 고지방 식이의 급여시 고지방 식이 단독 급여군에 비해 지방간의 병변이 뚜렷하게 억제된 것으로 관찰되었다. 부고환 지방의 경우는 감초 추출물 급여시 지방세포의 크기 감소가 관찰되었으며 갈색지방의 경우, 조직 무게의 감소가 세포내 지방 침착 억제에 의한 것임을 확인할 수 있었다 (도 8).
H & E stain of formalin fixed tissue sections for liver, epididymal fat (WAT), and brown fat (BAT) tissues showed a tendency to be observed in liver, weaning, , The fatty liver lesions were significantly inhibited compared to the high fat diet alone group. In the case of epididymal fat, the size of adipocyte was decreased when the licorice extract was fed, and in the case of brown fat, it was confirmed that the decrease in tissue weight was due to inhibition of intracellular fat deposition (FIG. 8).
(마) 혈중 지질 변화(E) Blood lipid changes
감초 추출물 급여가 혈중 지질 함량에 미치는 영향을 측정한 결과 (도 9), N-E에 비해 C-E군에서 TG, TC, HDL-C 및 LDL-C의 유의적 증가가 관찰되었다. TG의 경우는 W-E, SL-E 군에서만 유의적으로 감소되었으나 TC, LDL-C 및 NEFA의 경우는 모든 감초 추출물 급여 군에서 유의적으로 감소하여 혈중 지질 조절 효능이 높은 것으로 사료되었다.
A significant increase in TG, TC, HDL-C and LDL-C was observed in the CE group compared to NE (Fig. 9), when the effect of the licorice extract on the lipid content of the blood was measured TG was significantly decreased in the WE and SL-E groups, but TC, LDL-C and NEFA were significantly decreased in all the licorice extract-fed groups, suggesting that the lipid-modulating effect was high.
(바) 혈당, 혈청 호르몬 및 효소 활성(F) Blood sugar, serum hormone and enzyme activity
혈액에서의 혈당의 그룹별 차이는 관찰되지 않았으며 이는 절식 없이 최대 운동 수행능 평가 후 채혈하였기 때문으로 사료되었다. 혈중 렙틴(leptin)은 감초 추출물 투여군 모두에서 유의적으로 감소하였으며 특히, 지구력 증진 효과가 뛰어났던 SH-E 군에서 가장 낮은 수치를 보였다. 글리코겐 또는 포도당이 분해되어 ATP를 형성하는 과정에서 세포내에 충분한 양의 산소가 공급되지 못하면 혐기적 대사의 결과로 젖산이 축적됨에 따라 LDH의 활성이 증가하게 되며 또한 LDH는 근육손상의 대표적 마커이다. C-E 그룹에서는 N-E 그룹에 비해 혈청 LDH의 유의적 증가가 나타났으며 감초 추출물 급여 군에서 모두 효과적으로 억제된 것이 관찰되었다. 즉 감초 추출물 급여시 지구력 운동 결과 유도되는 근육 손상에 대해 보호 작용이 있는 것으로 사료되었다. 항산화 효소인 SOD의 경우 C-E 군에 비해 감초 추출물을 급여한 모든 군에서 증가하는 경향을 보였으나 유의적이지는 않았다 (표 2).There was no difference in blood glucose between groups in the blood, which is considered to be due to blood collection after evaluation of maximal exercise performance without fasting. Serum leptin was significantly decreased in the licorice extract-treated group, especially in the SH-E group, which had excellent endurance-enhancing effects. If glycogen or glucose is decomposed and ATP is not supplied enough oxygen in the cell, the accumulation of lactic acid as a result of anaerobic metabolism will increase the activity of LDH, and LDH is a representative marker of muscle damage. Serum LDH was significantly increased in the C-E group compared with the N-E group, and all of them were effectively inhibited in the licorice extract-fed group. In other words, it seems to be protective against muscle damage induced by endurance exercise when licorice extract is fed. The antioxidant enzyme, SOD, tended to increase in all groups fed the licorice extract compared to the C-E group, but not significantly (Table 2).
(사) 간 지질 변화(G) Liver lipid changes
간 조직의 총 지방량, TG, TC 및 NEFA를 분석한 결과 hepatic total lipid, hepatic TG, hepatic TG 및 NEFA에 대해, 감초 추출물은 고지방 식이 급여에 의한 혈중 지질 상승을 매우 효과적으로 억제하는 것으로 나타났다 (도 10).
Hepatic total lipid, hepatic TG, hepatic TG and NEFA showed that the licorice extract significantly inhibited the elevation of blood lipid levels by high fat diet (Table 10) ).
(아) 간의 운동 마커 변화(A) movement marker change between
무산소 운동시 ATP를 재합성하는데 필요한 크레아틴 포스페이트(creatine phosphate) 합성을 촉매하는 효소인 CPK는 근육손상의 마커로도 알려져 있다. C-E 그룹에서 상승한 CPK는 감초 추출물 급여 군에서 유의적으로 감소하였다. 간 글리코겐의 경우 C-E 그룹에서 현저히 높은 것은 고지방 식이 급여로 인해 과잉 에너지가 글리코겐의 형태로 간에 저장되어 지방간 병변으로 발전했기 때문이다. 이 외에도 최대 운동 후 간을 적출하여 상대적으로 적은 양의 운동을 수행한 C-E 그룹은 간의 글리코겐의 사용을 많이 하지 않은 것도 하나의 원인으로 사료되었다 (도 11).
CPK, an enzyme that catalyzes the synthesis of creatine phosphate required for the re-synthesis of ATP during anaerobic exercise, is also known as a marker of muscle damage. The CPK increased in the CE group significantly decreased in the licorice extract group. In the case of liver glycogen, a significantly higher level in the CE group is due to the fact that the excess energy is stored in the form of glycogen in the liver due to the high fat diet and developed into fatty liver lesions. In addition, the CE group, which performed a relatively small amount of exercise after the maximal exercise, was considered to be one of the reasons for not using much glycogen in the liver (Fig. 11).
(자) 근육의 운동 마커 변화(A) Movement marker of muscle
최대 운동 수행 후 근육내 젖산 및 글리코겐의 농도를 측정하였음 (도 12). 젖산은 무산소 운동 중에 근세포질에 축적되는 피로물질로서 운동에 의해 체내에 축적시 체내 환경의 산성화를 통해 운동에너지의 급원이 되는 당신생의 억제를 유도한다. C-E 그룹의 경우 근육의 젖산 축적이 증가하였으나 감초 추출물을 급여한 운동군에서는 젖산의 축적이 감소되는 경향을 보였다.The concentration of lactate and glycogen in the muscle was measured after maximal exercise (Fig. 12). Lactic acid is a fatigue substance that accumulates in myocytes during anaerobic exercise. When accumulated in the body by exercise, it induces the inhibition of your life which becomes a source of kinetic energy through acidification of the body environment. In the C-E group, accumulation of lactic acid in the muscle was increased, but accumulation of lactic acid in the exercise group with the licorice extract was decreased.
근육의 글리코겐 농도는 지구력 운동수행능력에 영향을 미치는 요인으로 알려져 있는데, 본 실험 결과 감초추출물 투여 군에서 C-E 군에 비해 오히려 근육 내 글리코겐 농도가 감소한 것으로 나타났다. 이는 마우스를 탈진시까지 운동을 시킨 후 근육을 채취하였는데, 탈진시까지의 운동거리가 C-E 군에서 다른 실험군에 비해 유의적으로 짧았기 때문에 상대적으로 근육의 글리코겐이 덜 고갈되었기 때문으로 사료되었다.
The concentration of glycogen in muscles is known to be a factor affecting endurance exercise performance. In this experiment, the concentration of glycogen in muscle was decreased rather than that of CE group. This was because the exercise distance until the burnout was significantly shorter in the CE group than in the other experimental groups, suggesting that the glycogen in the muscle was depleted relatively.
(차) Muscle fiber type transitionMuscle fiber type transition
속근 (fast and glycolytic)의 type II 근육의 대표적 근육인 비복근 (gastronemius m.)의 운동 후 변화를 측정하고자 지근 (slow and aerobic type I muscle) 마커인 트로포닌 I(troponin I)과 속근 마커인 MyHCIIb의 유전자 발현을 측정한 결과 운동 후 감초 추출물 급여군에서 속근이 줄어들고 지근이 증가하는 경향을 나타냈다 (도 13).
To investigate the post-exercise changes of the gastrocnemius muscles, which are the representative muscles of fast and glycolytic type II muscles, troponin I, a slow and aerobic type I muscle marker, and MyHCIIb, a fasting marker, (Fig. 13). As a result, the fasting tendency was decreased and the root was increased in the licorice extract-fed group (Fig. 13).
(카) 호흡량 및 호흡률 변화(K) Changes in volume and respiration rate
체중변화에 미치는 호흡율 영향을 알아보기 위해, 각 그룹의 마우스를 저녁 7시부터 오전 7시까지 12시간 동안 calorimetry로 VO2, VCO2 및 RQ (respiroatory quotient, 호흡율)를 측정한 결과는 도 14와 같다. N 그룹은 C 그룹에 비해 RQ가 상승하는 경향을 보였으나 유의적이지는 않았다. W-E 그룹의 경우 VO2 및 VCO2 모두 증가되어 RQ는 유지되었다. SL 및 SH 그룹도 VO2 및 VCO2 모두 증가되는 경향을 보였으나 유의적 차는 없었다.
In order to investigate the effect of respiratory rate on weight change, VO 2 , VCO 2 and respiratory quotient (RQ) were measured by calorimetry for 12 hours from 7:00 PM to 7:00 AM in each group, same. The N group tended to have a higher RQ than the C group, but it was not significant. For the WE group, VO 2 and VCO 2 All were increased and RQ was maintained. The SL and SH groups also include VO 2 and VCO 2 All showed a tendency to increase but no significant difference.
<실험예 3><Experimental Example 3>
얼레지 열수추출물 5 중량%와 감초 열수추출물 5 중량%를 포함하는 본 발명의 지구력 내지 운동능력 증진용 조성물(A)을 성숙한 지방세포에 48시간 처리한 후 DAPI 염색하여 지방세포의 세포사멸 유도 효능을 평가한 결과 지방세포의 세포사멸이 얼레지 열수추출물을 함유하지 않은 감초 열수추출물 10중량%를 포함하는 지구력 내지 운동능력 증진용 조성물(C)에 비하여 증가한 것으로 확인되었다 (도 15).The composition for improving endurance or athletic performance (A) of the present invention comprising 5% by weight of hot water extract and 5% by weight of hot water extract of licorice was treated with mature fat cells for 48 hours and then dyed with DAPI to induce apoptosis induction of adipocytes As a result of the evaluation, it was confirmed that the apoptosis of the adipocyte was increased as compared with the composition for improving endurance or athletic performance (C) containing 10% by weight of the liquorice hot water extract containing no hot water extract (Fig. 15).
상기와 같이, 본 발명의 바람직한 실시 예를 참조하여 설명하였지만 해당 기술 분야의 숙련된 당업자라면 하기의 특허청구범위에 기재된 본 발명의 사상 및 영역으로부터 벗어나지 않는 범위 내에서 본 발명을 다양하게 수정 및 변경시킬 수 있음을 이해할 수 있을 것이다.
While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it will be understood by those skilled in the art that various changes and modifications may be made without departing from the spirit and scope of the invention as defined in the appended claims. It can be understood that
Claims (1)
A composition for inhibiting obesity comprising an extract of licorice and an extract of an extract as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020130106321A KR101436753B1 (en) | 2013-09-04 | 2013-09-04 | Anti obesity composition comprising licorice extracts and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020130106321A KR101436753B1 (en) | 2013-09-04 | 2013-09-04 | Anti obesity composition comprising licorice extracts and preparation method thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020100065690A Division KR20120005111A (en) | 2010-07-08 | 2010-07-08 | Athletic ability enhancing composition comprising licorice extracts and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20140014027A KR20140014027A (en) | 2014-02-05 |
KR101436753B1 true KR101436753B1 (en) | 2014-09-02 |
Family
ID=50264262
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020130106321A KR101436753B1 (en) | 2013-09-04 | 2013-09-04 | Anti obesity composition comprising licorice extracts and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101436753B1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110115861A (en) * | 2010-04-16 | 2011-10-24 | 전남대학교산학협력단 | Germinated brown rice for prevention of obesite and method of production thereof |
-
2013
- 2013-09-04 KR KR1020130106321A patent/KR101436753B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110115861A (en) * | 2010-04-16 | 2011-10-24 | 전남대학교산학협력단 | Germinated brown rice for prevention of obesite and method of production thereof |
Also Published As
Publication number | Publication date |
---|---|
KR20140014027A (en) | 2014-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101054594B1 (en) | Liver Function Enhancer Composition | |
KR20160017223A (en) | Composition for muscle development and muscle fatigue recovery comprising Angelica keiskei extract and Red ginseng extract as active ingradients | |
KR101523663B1 (en) | A composition for preventing or treating fatty liver disease or obesity, comprising a extract of Arctium lappa Linne, Glycyrrhiza uralensis Fischer, Zingiberis rhizoma Crudus and Magnoliae Cortex | |
KR102225574B1 (en) | Composition for preventing, treating or improving obesity or obesity-related disease comprising extracts of Angelica tenuissima | |
KR101415697B1 (en) | A pharmaceutical composition comprising the combined extract of Crataegi Fructus and Citri Pericarpium for treating or preventing obesity or lipid-related metabolic disorder | |
KR101685438B1 (en) | A composition comprising an extract of Hippophae rhamnoides for improving physical fatigue, and exercise performance ability | |
KR101675064B1 (en) | A composition comprising the complex extract for enhancing power of exercise performance and promoting physical stamina | |
KR20160141027A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder | |
KR101446528B1 (en) | Vinegar Composition Fermented with Black Garlic and Preparation Method Thereof | |
KR102099147B1 (en) | Composition for preventing, ameliorating or treating obesity comprising Heracleum moellendorffii root and Torilis japonica mixed extract as effective component | |
KR100851586B1 (en) | Composition comprising Lactobacillus for inhibiting obesity | |
KR101350046B1 (en) | Vinegar composition fermented with herbal extracts and preparation method thereof | |
JP2017522372A (en) | A composition for improving muscle function or enhancing exercise performance, comprising a kilenol or sigez vecchia herb extract | |
KR101436753B1 (en) | Anti obesity composition comprising licorice extracts and preparation method thereof | |
KR20190053108A (en) | A composition comprising the complex extract for antiobesity of men | |
KR20120005111A (en) | Athletic ability enhancing composition comprising licorice extracts and preparation method thereof | |
KR102235563B1 (en) | Composition for fatigue recovery and sexual function improvement containing high content of arginine | |
WO2008069604A1 (en) | Composition comprising the mixed herbal extract of aralia cordata thunb. and cimicifuga heracleifolia kom. for preventing and treating inflammatory disease and pain disease | |
KR20190001112A (en) | Anti-obesity composition comprising Protaetia brevitarsis seulensis larva extracts | |
KR20140036966A (en) | Composition for improving exercise capacity or a composition for reducing fatigue using leaves of sasa quelpaertensis | |
KR101445485B1 (en) | A composition comprising the combined extract of Curcuma Longa L. and Nelumbo nucifera as an active ingredient showing anti-obesity and anti-hypercholesterolemia activity | |
KR101421347B1 (en) | A method for preparing the essential oil fraction showing potent anti-obesity and inhibiting activity on fatty liver from Angelica gigas Nakai and the composition comprising the same the prevention or treatment of obesity and fatty liver | |
KR101336068B1 (en) | Anti-diabetes composition comprising oriental herbal extracts and fractions | |
KR101001159B1 (en) | Composition for preventing or improving the diabete containing eriobotrya japonica extract | |
KR20200014567A (en) | A composition for improving, preventing and treating of liver diseases comprising Milk thistle |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
FPAY | Annual fee payment |
Payment date: 20170908 Year of fee payment: 4 |